The Tough Tech problem we are solving
Cell and gene therapy development stalls at scalability, from discovery to biomanufacturing, due to inefficient, costly genome engineering that fails to deliver materials to therapeutic cells quickly, reliably, and at volume.
About our solution
Kytopen's non-viral gene delivery platform fuses microfluidics and automation to accelerate discovery with high-throughput screening and enable large-scale production. We eliminate manufacturing barriers early, slashing costs and timelines to bring life-changing therapies to patients faster.